deltatrials
Unknown PHASE3 INTERVENTIONAL NCT00629278

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF 2 DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENS PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN HER2 POSITIVE BREAST CANCER PATIENTS

Sponsor: Azienda Ospedaliero-Universitaria di Modena

Conditions Breast Cancer
Interventions adjuvant therapy aromatase inhibition therapy cyclophosphamide docetaxel doxorubicin hydrochloride epirubicin hydrochloride fluorouracil paclitaxel radiation therapy releasing hormone agonist therapy tamoxifen citrate trastuzumab
Updated 6 times since 2017 Last updated: Aug 6, 2013 Started: Dec 31, 2007 Primary completion: Dec 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by Azienda Ospedaliero-Universitaria di Modena and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~May 2018 · 16 months · monthly snapshotUnknown Status~May 2018 – ~Jun 2018 · 31 days · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE3

  5. May 2018 — Jun 2018 [monthly]

    Unknown Status PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — May 2018 [monthly]

    Unknown Status PHASE3

    First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Azienda Ospedaliero-Universitaria di Modena
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations